Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Congress 2022 | Dynamic personalized thrombosis prediction in polycythemia vera

Ghaith Abu-Zeinah • 24 Nov 2022
MPN Congress 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Ghaith Abu-Zeinah, MD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, gives a presentation on dynamic personalized thrombosis prediction in polycythemia vera (PV) at the 14th International Congress on Myeloproliferative Neoplasms (MPNs) held in New York City, NY.

More from Ghaith Abu-Zeinah

Updates on the use of ropeginterferon in the treatment of MPNs 15:45
Updates on the use of ropeginterferon in the treatment of MPNs
Ghaith Abu-Zeinah • 29 Aug 2024
A meta-analysis assessing the safety of cytoreductive therapies in younger patients with PV 6:31
A meta-analysis assessing the safety of cytoreductive therapies in younger patients with PV
Ghaith Abu-Zeinah • 29 Aug 2024
The potential use of molecular response as a surrogate marker for survival outcomes in MPNs 2:00
The potential use of molecular response as a surrogate marker for survival outcomes in MPNs
Ghaith Abu-Zeinah • 29 Aug 2024
A new machine learning prediction model for thrombosis risk in polycythemia vera 3:42
A new machine learning prediction model for thrombosis risk in polycythemia vera
Ghaith Abu-Zeinah • 3 Nov 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals